Haemonetics Stock Performance
| HAE Stock | USD 65.23 0.55 0.85% |
The company retains a Market Volatility (i.e., Beta) of 0.5, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Haemonetics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Haemonetics is expected to be smaller as well. At this point, Haemonetics has a negative expected return of -0.25%. Please make sure to check out Haemonetics' standard deviation, maximum drawdown, kurtosis, as well as the relationship between the total risk alpha and potential upside , to decide if Haemonetics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Haemonetics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (0.76) | Five Day Return (2.74) | Year To Date Return (18.12) | Ten Year Return 44.21 | All Time Return 981.09 |
Last Split Factor 2:1 | Last Split Date 2012-12-03 |
1 | Are You a Growth Investor This 1 Stock Could Be the Perfect Pick | 01/17/2025 |
2 | Disposition of 161 shares by Roy Galvin of Haemonetics at 71.48 subject to Rule 16b-3 | 01/28/2025 |
3 | Haemonetics Reaches New 52-Week Low Heres Why | 02/05/2025 |
4 | Haemonetics Corporation Q3 2025 Earnings Call Transcript | 02/07/2025 |
5 | Bausch Lomb Reports Earnings Tomorrow What To Expect | 02/18/2025 |
6 | CSL Receives Approval in Japan for ANDEMBRY Subcutaneous Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of... | 02/20/2025 |
7 | US Stocks Trading Below Estimated Value In February 2025 | 02/21/2025 |
8 | The European Medicines Agency Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO for Patients Aged 12 Years and Above with Recurrent Att... | 02/24/2025 |
9 | Haemonetics Corp Stock Price Up 4.6 percent on Feb 25 | 02/25/2025 |
10 | Sotera Health Reports Fourth-Quarter and Full-Year 2024 ResultsProvides 2025 Outlook | 02/27/2025 |
11 | Haemonetics Names Chan Chief Operating Officer | 03/03/2025 |
12 | Haemonetics Corp Shares Down 3.63 percent on Mar 12 | 03/12/2025 |
13 | Acquisition by Bryant Diane M of 2207 shares of Haemonetics subject to Rule 16b-3 | 03/13/2025 |
14 | Is it Apt to Retain HAE Stock in Your Portfolio for Now | 03/18/2025 |
| Begin Period Cash Flow | 284.5 M | |
| Free Cash Flow | 115.5 M |
Haemonetics |
Haemonetics Relative Risk vs. Return Landscape
If you would invest 7,690 in Haemonetics on December 19, 2024 and sell it today you would lose (1,222) from holding Haemonetics or give up 15.89% of portfolio value over 90 days. Haemonetics is generating negative expected returns assuming volatility of 2.6338% on return distribution over 90 days investment horizon. In other words, 23% of stocks are less volatile than Haemonetics, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Haemonetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Haemonetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Haemonetics, and traders can use it to determine the average amount a Haemonetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.096
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HAE |
Estimated Market Risk
| 2.63 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Haemonetics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Haemonetics by adding Haemonetics to a well-diversified portfolio.
Haemonetics Fundamentals Growth
Haemonetics Stock prices reflect investors' perceptions of the future prospects and financial health of Haemonetics, and Haemonetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Haemonetics Stock performance.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0633 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 4.15 B | ||||
| Shares Outstanding | 50.24 M | ||||
| Price To Earning | 50.35 X | ||||
| Price To Book | 3.58 X | ||||
| Price To Sales | 2.37 X | ||||
| Revenue | 1.31 B | ||||
| Gross Profit | 768.33 M | ||||
| EBITDA | 265.58 M | ||||
| Net Income | 117.56 M | ||||
| Cash And Equivalents | 284.47 M | ||||
| Cash Per Share | 4.79 X | ||||
| Total Debt | 807.79 M | ||||
| Debt To Equity | 1.12 % | ||||
| Current Ratio | 2.73 X | ||||
| Book Value Per Share | 18.05 X | ||||
| Cash Flow From Operations | 181.75 M | ||||
| Earnings Per Share | 2.54 X | ||||
| Market Capitalization | 3.26 B | ||||
| Total Asset | 2.2 B | ||||
| Retained Earnings | 360.46 M | ||||
| Working Capital | 468.52 M | ||||
| Current Asset | 488.09 M | ||||
| Current Liabilities | 185.55 M | ||||
About Haemonetics Performance
By analyzing Haemonetics' fundamental ratios, stakeholders can gain valuable insights into Haemonetics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Haemonetics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Haemonetics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 119.29 | 117.23 | |
| Return On Tangible Assets | 0.05 | 0.08 | |
| Return On Capital Employed | 0.07 | 0.06 | |
| Return On Assets | 0.04 | 0.07 | |
| Return On Equity | 0.06 | 0.10 |
Things to note about Haemonetics performance evaluation
Checking the ongoing alerts about Haemonetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Haemonetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Haemonetics generated a negative expected return over the last 90 days | |
| Haemonetics is unlikely to experience financial distress in the next 2 years | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Is it Apt to Retain HAE Stock in Your Portfolio for Now |
- Analyzing Haemonetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Haemonetics' stock is overvalued or undervalued compared to its peers.
- Examining Haemonetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Haemonetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Haemonetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Haemonetics' stock. These opinions can provide insight into Haemonetics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |